RallyBio, a New Haven biopharma company, announced a new round of layoffs. Nine employees, representing 40% of its workforce, will be cut in the coming months. The company aims to streamline operations and pivot its dr-g programs. This strategic shift focuses on a dr-g candidate nearing clinical trials. RallyBio previously discontinued a dr-g for a rare newborn disease.
https://www.stamfordadvocate.com/business/article/ct-rallybio-new-haven-layoffs-biopharma-20319026.php?utm_content=hed&sid=&ss=P&st_rid=null&utm_source=newsletter&utm_medium=email&utm_campaign=CT_AD_NewsNow